Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics Ltd. has initiated a Phase 2 clinical trial for its drug Quilience (mazindol ER) targeting excessive daytime sleepiness and cataplexy in narcolepsy patients. Enrolling around 60 patients across 30 centers in the U.S. and Europe, the trial aims to assess its efficacy over 28 days. Primary endpoints include changes in the Epworth Sleepiness Scale and cataplexy attack frequency. Successful completion could lead to significant advancements in treatment options for narcolepsy, addressing an unmet medical need.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NASDAQ:NLSPW) announces that CEO Alex Zwyer will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Investors can access the presentation online starting September 13 at 1:00 PM CET / 7:00 AM ET. This conference includes six industry tracks, highlighting Healthcare & Biotechnology, and offers networking opportunities. NLS is focused on innovative therapies for central nervous system disorders, with its lead candidate, Quilience, targeting narcolepsy and receiving Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced a Notice of Allowance from the USPTO for patent application No. 16/083,131.
This patent will cover oral formulations with immediate-release and sustained-release layers of mazindol for treating attention deficit disorders (ADD, ADHD), narcolepsy, and excessive daytime sleepiness.
The patent is expected to issue in Q4 2021, expiring no earlier than March 2037. NLS aims to include it in the FDA's Orange Book if market approval is obtained.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced that CEO Alex Zwyer will present at the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. Zwyer's presentation is scheduled for August 12, 2021, at 10:00 AM ET and will be available for live streaming and replay on the company's website. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead product, Quilience, developed for narcolepsy treatment and holding orphan drug designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. has appointed Eric Konofal, M.D., Ph.D., as Chief Scientific Officer. Dr. Konofal, a co-founder with over 30 years of experience in CNS disorders, will focus on advancing the company’s drug pipeline, which includes Quilience® for narcolepsy and five other patented compounds. His leadership is expected to enhance drug development efforts, particularly against disorders like ADHD and Parkinson’s disease. The company recently submitted multiple patent applications, which could strengthen its market position.
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) announced that the FDA has accepted its Investigational New Drug application for Quilience (mazindol ER), the lead candidate for treating narcolepsy. The company plans to launch a Phase 2a clinical trial in August 2021 across the U.S. and Europe, enrolling about 60 patients. The primary objective is to assess changes in excessive daytime sleepiness using the Epworth Sleepiness Scale, with secondary endpoints related to cataplexy attacks. This milestone emphasizes NLS's commitment to developing treatments for central nervous system disorders.
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced that CEO Alex Zwyer will present a corporate overview at the First Annual Access to Giving Virtual Investor Conference from July 13-15, 2021. The presentation is scheduled for July 15th at 9:00 am ET, followed by a Q&A session. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead candidate, Quilience®, aimed at treating narcolepsy, receiving Orphan Drug Designations in the U.S. and Europe.
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Alex Zwyer is set to deliver the presentation on June 10 at 11:30 AM ET on Track 2. The company's lead product, Quilience®, a controlled-release formulation of mazindol, is designed to treat narcolepsy and has received Orphan Drug Designations in both the U.S. and Europe. NLS completed a successful Phase 2 study on mazindol CR for ADHD, meeting all study endpoints.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is set to present a corporate overview at the MicroCap Rodeo 2021 Summer Solstice Conference from June 1-4, 2021. CEO Alex Zwyer will deliver the presentation on June 2 at 8:30 AM ET and will engage in one-on-one meetings throughout the event. The presentation will be webcast live, with a replay available for later viewing. NLS is focused on developing therapies for rare central nervous system disorders, with its lead product candidate, Quilience®, targeting narcolepsy. For more details and to register, visit the company’s website.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) announced new study data confirming mazindol's mechanism of action as an Orexin-2 receptor (OX2R) agonist, essential for treating narcolepsy. In a pre-clinical study, genetically modified mice demonstrated significantly reduced sensitivity to mazindol, reinforcing its potent neurochemical activity. Ongoing studies aim to expand on these findings, emphasizing mazindol's potential dual mechanism of action in addressing narcolepsy's core symptoms. The company remains committed to developing Quilience®, a controlled-release formulation of mazindol, with hopes of improving treatment efficacy.
FAQ
What is the current stock price of Nls Pharmaceutics (NLSP)?
What is the market cap of Nls Pharmaceutics (NLSP)?
